10 Eli Lilly regulatory affairs leaders
Jeffrey Francer, Vice President, Head of International Regulatory Affairs & Global Regulatory Policy, leads this list of Eli Lilly regulatory affairs leaders, whose other titles cover global regulatory affairs, Americas regional work and devices and diagnostics. A reader can learn how regulatory affairs leaders work at Eli Lilly from people who have held the role.
Professionals to explore
ChiaYee Ang
LinkedInExperience: Director, Global Regulatory Affairs-Devices Deliver Device, Digital Health & Diagnostics · Eli Lilly and Company
ChiaYee Ang has been Director, Global Regulatory Affairs-Devices Deliver Device, Digital Health & Diagnostics at Eli Lilly and Company since October 2025, based in Greater Indianapolis. At Eli Lilly and Company, ChiaYee Ang was Sr. Advisor, Global Regulatory Affairs-Devices Deliver Device, Digital Health & Diagnostics from 2023 to 2025 and Advisor, Global Regulatory Affairs-Devices Deliver Device & Digital Health from 2021 to 2023.
Erika Barkley
LinkedInExperience: Director, Global Regulatory Affairs · Eli Lilly and Company
Erika Barkley has been Director, Global Regulatory Affairs at Eli Lilly and Company since March 2025, based in Indianapolis, Indiana. At Eli Lilly and Company, Erika Barkley was Associate Director, Global Regulatory Affairs from 2023 to 2025, Senior Advisor - Global Regulatory Affairs - CMC from 2022 to 2023 and Senior Research Scientist - Global Regulatory Affairs from 2020 to 2022.
Jean Y Chen, M. Eng, MBA, RAC
LinkedInExperience: Director Global Regulatory Affairs - Devices, Diagnostics · Eli Lilly and Company
Jean Y Chen has been Director Global Regulatory Affairs - Devices, Diagnostics at Eli Lilly and Company since June 2024, based in the San Francisco Bay Area. At Loxo@Lilly, Jean Y Chen was Executive Director, Regulatory Affairs from 2023 to 2024 and Director, Regulatory Affairs, CDx in 2022, and Jean Y Chen was Associate Director Regulatory Affairs at Guardant Health from 2021 to 2022.
Jeffrey Francer
LinkedInExperience: Vice President, Head of International Regulatory Affairs & Global Regulatory Policy · Eli Lilly and Company
Jeffrey Francer has been Vice President, Head of International Regulatory Affairs & Global Regulatory Policy at Eli Lilly and Company since March 2026 and was Vice President, Head of Global Regulatory Policy & Strategy there from 2023 to 2026. Jeffrey Francer was Senior Vice President and General Counsel at Association for Accessible Medicines from 2016 to 2022, based in Washington, District of Columbia.
Josephine Secnik
LinkedInExperience: Executive Director, Regulatory Affairs · Eli Lilly and Company
Josephine Secnik holds the title Executive Director, Regulatory Affairs at Eli Lilly and Company, listed from 1990 to the present, based in Greenwood, Indiana. The profile headline reads Executive Director, Regulatory Affairs at Eli Lilly and Company, and the listing shows no other roles, so check the full profile for the rest of the background.
Khalid Mahmood
LinkedInExperience: Director Global Regulatory Affairs · Eli Lilly and Company
Khalid Mahmood has been Director Global Regulatory Affairs at Eli Lilly and Company since October 2024, based in Carmel, Indiana. At Eli Lilly and Company, Khalid Mahmood held the title Research Scientist, Global Regulatory CMC Biotechnology from 2010 to 2024 and was Manager Quality Control from 2002 to 2010.
Lars C. Holzhausen
LinkedInExperience: Executive Director · Eli Lilly and Company
Lars C. Holzhausen has been Executive Director at Eli Lilly and Company since July 2024, and the profile headline reads Executive Director, Global Regulatory Affairs at Eli Lilly. At Loxo@Lilly, Lars C. Holzhausen was Associate Vice President from 2023 to 2024, Senior Director Regulatory Affairs from 2022 to 2023 and Director Regulatory Affairs from 2020 to 2022, based in Orinda, California.
Lydia Wilkinson
LinkedInExperience: Senior Director - Regulatory Affairs, Americas - Cardiometabolic Health · Eli Lilly and Company
Lydia Wilkinson has been Senior Director - Regulatory Affairs, Americas - Cardiometabolic Health at Eli Lilly and Company since December 2024, based in Indianapolis, Indiana. At Eli Lilly and Company, Lydia Wilkinson held the title Regulatory Scientist, FDA and Health Canada (Immunology, Neuroscience) from 2022 to 2025 and was Global Pharmaceutical Project Manager - Associate Director (Neuroscience) in 2022.
Mitchell R. Cunningham
LinkedInExperience: Senior Director, Global Regulatory Affairs | Americas GI Lead · Eli Lilly and Company
Mitchell R. Cunningham has been Senior Director, Global Regulatory Affairs | Americas GI Lead at Eli Lilly and Company since January 2025, based in Indianapolis, Indiana. At Eli Lilly and Company, Mitchell R. Cunningham was Regulatory Scientist - Global Regulatory Affairs from 2021 to 2025 and Associate Consultant - BioMedicines Pharmaceutical Project Manager from 2019 to 2021.
Patricia Sondergaard
LinkedInExperience: Executive Director · Eli Lilly and Company
Patricia Sondergaard has been Executive Director at Eli Lilly and Company since January 2025, and the profile headline reads Senior Director, Global Regulatory Affairs at Eli Lilly and Company. At Prevail Therapeutics, Patricia Sondergaard was Executive Director, Global Regulatory Affairs from 2023 to 2025, Senior Director Regulatory Affairs from 2021 to 2023 and Director, Global Regulatory Affairs from 2019 to 2021.
Choose the right perspective
Match the scope named in a person's title, such as global regulatory policy, the Americas or devices and diagnostics, to the question you need answered. Weigh how close the scope of each person's role is to the decision you face.
Questions to take into the conversation
- 01What did you focus on first when you took on your regulatory affairs role at Eli Lilly?
- 02What decision in your Eli Lilly regulatory affairs role would you make differently today, and why?
- 03What has your own work at Eli Lilly taught you about building a regulatory affairs team?
Reaching Eli Lilly regulatory affairs leaders
How can I contact one of these Eli Lilly regulatory affairs leaders?
Pick one of the 10 people on this page and choose "Book a paid call", or describe your project to find others. You offer a fee for a 15-minute call or a written answer, Instant Expert finds the person's work email and sends the invitation, and they decide whether to accept. The list covers 1 company: Eli Lilly and Company, based on profile data retrieved on October 24, 2026. Being listed here doesn't mean someone has agreed to take calls.
How much does it cost to reach Eli Lilly regulatory affairs leaders?
You choose the offer, starting at $5 per person. The offer is what the person receives, and Instant Expert's fee is added on top, so a $100 offer costs you $125. The fee is 20% of what you pay. You're charged only when the person books the call or sends the answer.
What if they don't reply?
You pay nothing. Instant Expert sends follow-up reminders, and if the person hasn't booked or answered within 7 days, the request expires and any hold on your card is released. You can invite several of the 10 people on this list at once and cap your total spend, so you pay only for the ones who accept.
Can an AI agent ask one of these Eli Lilly regulatory affairs leaders a question?
Yes. An agent with a USDC wallet on Base can ask one question without an Instant Expert account. It names the person, for example by the LinkedIn URL on this page, and pays per ask over x402 (HTTP 402). The person answers in writing or by voice note, and if nobody answers within 7 days, the payment goes back to the wallet automatically. Claude and ChatGPT can do the same through the Instant Expert connector: setup is at /docs/mcp for Claude and /docs/chatgpt for ChatGPT. x402 docs
About this directory
This is a professional research starting point based on business profile data retrieved on . Titles and companies reflect that source snapshot; roles marked former had ended by then. Check the linked profiles for current details. Inclusion does not imply Instant Expert membership or availability.
Request a correction or removal